Sort
51,593 grants matching “hepatitis”
Center for the Study of Innate Immunity to HCV Infection
$858,518Michael J Gale · University Of Washington · U19 · FY2014 · AI
Regulation of Liver by Nuclear Ca2+ Signaling
$858,368Yale University · P01 · FY2002 · DK
A Role for the Novel HAF-NFkappaB Axis in Driving Obesity-Associated Liver Cancer
$858,089Mei Yee Koh · Utah State Higher Education System--University Of Utah · R01 · FY2025 · CA
Saliva Analysis with an Array Sensor
$857,714University Of Texas Austin · U01 · FY2004 · DE
A smartphone-enabled point-of-care HCV Ag diagnostic using catalytic nanoparticles and AI-enhanced image processing
$857,686Hadi Shafiee · Brigham And Women'S Hospital · R01 · FY2025 · EB
Simulating Protein Structures, Complexes, And Dynamics
$857,662Peter J Steinbach · Center For Information Technology · ZIA · FY2019 · CT
Clinical Research Network in Non-Alcoholic Steatohepatitis
$857,613James A Tonascia · Johns Hopkins University · U01 · FY2008 · DK
Cardiovascular Risk Reduction in an Aging HIV-Infected Population: The Impact of HCV Co-Infection
$857,509Virginia Athena Triant · Massachusetts General Hospital · R01 · FY2019 · AG
The impact of intravenous heroin use on immune activation in treated HIV
$857,236Grace A McComsey · Case Western Reserve University · R01 · FY2021 · DA
Preclinical development of a chemopreventive agent, 4-methylumbelliferone(4-MU) HHSN2512015000361 TORFP: 2018-E07 PP: 9/17/18 to 9/16/19
$857,168Clinton Grubbs · University Of Alabama At Birmingham · N01 · FY2019 · CA
Nucleic Acid Footprinting and development of small molecule antagonists
$856,937Stuart F. J. Le Grice · Division Of Basic Sciences - Nci · ZIA · FY2019 · CA
The impact of intravenous heroin use on immune activation in treated HIV
$856,800Grace A McComsey · Case Western Reserve University · R01 · FY2020 · DA
Development of an engineered CCL20 protein as a lead therapeutic molecule for psoriasis
$856,782Chad Allen Koplinski · Xlock Biosciences, Llc · R44 · FY2020 · AR
Regulation of host innate and adaptive immunity by bacterial type III effectors
$856,414James B Bliska · Dartmouth College · R01 · FY2025 · AI
The role of apolipoproteins in viral entry and human disease
$856,275Joseph Marcotrigiano · National Institute Of Allergy And Infectious Diseases · ZIA · FY2025 · AI
Entry and replication of positive-sense, RNA viruses
$856,275Joseph Marcotrigiano · National Institute Of Allergy And Infectious Diseases · ZIA · FY2025 · AI
Preclinical Development of SB 44 as an Orally Bioavailable Anti-HBV Agent
$856,160Radhakrishnan P Iyer · Spring Bank Technologies, Inc. · R01 · FY2014 · AI
PUFAs and gene variation affecting aspirin antiplatelet response
$855,921Kenneth E. Thummel · University Of Washington · P01 · FY2018 · GM
Revolutionary Eilat-based Chikungunya Vaccine Vector
$855,817Tian Wang · University Of Texas Med Br Galveston · R01 · FY2017 · AI
Pathogenesis of HIV and HCV in Hemophilia: HGDS
$855,816Children'S Hospital Los Angeles · R01 · FY2001 · HD
Xenobiotic Receptors in Mediating the Environmental Effects on Human Disease and Morbidity
$855,738Wen Xie · University Of Pittsburgh At Pittsburgh · R35 · FY2023 · ES
Vaccine and Treatment Evaluation Unit at Saint Louis University
$855,721Daniel F. Hoft · Saint Louis University · UM1 · FY2023 · AI
The impact of intravenous heroin use on immune activation in treated HIV
$855,636Grace A McComsey · Case Western Reserve University · R01 · FY2019 · DA
Cost-Effectiveness of Preventing HIV Complications
$855,309Kenneth Alan Freedberg · Massachusetts General Hospital · R01 · FY2019 · AI
In vitro modeling to characterize mechanisms of neonatal vaccine induced immune responses
$855,154Ofer Levy · Boston Children'S Hospital · U19 · FY2021 · AI